MAPK/ERK Pathway Immunology/Inflammation Autophagy Epigenetics Neuronal Signaling NF-κB Protein Tyrosine Kinase/RTK Stem Cell/Wnt PI3K/Akt/mTOR Metabolic Enzyme/Protease Apoptosis JAK/STAT Signaling
JNK Reactive Oxygen Species (ROS) VEGFR p38 MAPK PI3K Apoptosis Amyloid-β STAT Akt Autophagy JAK HIF/HIF Prolyl-Hydroxylase
Liensinine

Cat. No.: HY-N0484

Liensinine

21 Cited Publications

Avis client

Based on 21 publication(s) in Google Scholar

Liensinine is a bisbenzylisoquinoline alkaloid. By inhibiting the PI3K/AKT and JNK/p38-MAPK signaling pathways, Liensinine suppresses autophagy and apoptosis, clears Aβ, and exerts anti-inflammatory, antioxidant and neuroprotective effects. Liensinine activates AMPK and inhibits the expression of HIF-1α and VEGF, thereby suppressing angiogenesis. Liensinine exerts anti-tumor effects through ROS-mediated inhibition of the JAK2/STAT3 signaling pathway. Liensinine can be used for the research of diseases such as Alzheimer's disease, hepatocellular carcinoma, osteosarcoma, sepsis-induced organ injury and stroke.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.97%
CAS No.: 2586-96-1
Formule: C₃₇H₄₂N₂O₆
Masse moléculaire:610.74

Stockage:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Liensinine Chemical Structure

CAS No.: 2586-96-1

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (21)
Solvant et solubilité
- In Vitro
- In Vivo
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

Voir tous les produits spécifiques à Isoform JNK :

Voir tous les produits spécifiques à Isoform VEGFR :

Voir tous les produits spécifiques à Isoform p38 MAPK :

Voir tous les produits spécifiques à Isoform PI3K :

Voir tous les produits spécifiques à Isoform STAT :

Voir tous les produits spécifiques à Isoform Akt :

Voir tous les produits spécifiques à Isoform JAK :

Voir tous les produits spécifiques à Isoform HIF/HIF Prolyl-Hydroxylase :

Cellular Effect

Cell Line	Type	Value	Description	References
3T3-L1	IC₅₀	19.4 μM Compound: 9	Anti-adipogenic activity in mouse 3T3-L1 cells transfected with Lenti-PPARgamma-Luc reporter assessed as inhibition of PPARgamma expression by luminescence based microplate reader analysis Anti-adipogenic activity in mouse 3T3-L1 cells transfected with Lenti-PPARgamma-Luc reporter assessed as inhibition of PPARgamma expression by luminescence based microplate reader analysis	[PMID: 38483204]

In Vitro

Liensinine (5-80 μM; 24 h) reduces the viability of SaOS-2, MG-63, 143B and U-2OS osteosarcoma cells in a dose-dependent manner, but has no effect on the viability of hFOB 1.19 normal osteoblasts^[1].
Liensinine (40-80 μM; 24 h) inhibits the proliferation and colony-forming ability of SaOS-2 and 143B osteosarcoma cells, induces apoptosis, and causes G0/G1 cell cycle arrest in a dose-dependent manner^[1].
Liensinine (40-80 μM; 24 h) increases intracellular ROS production in SaOS-2 and 143B osteosarcoma cells in a dose-dependent manner, but does not affect ROS levels in hFOB 1.19 normal osteoblasts^[1].
Liensinine (40-80 μM; 24 h) disrupts the GSH/GSSG redox balance in SaOS-2 and 143B osteosarcoma cells in a dose-dependent manner by decreasing GSH levels, increasing GSSG levels, and elevating the GSSG/GSH ratio^[1].
Liensinine (40-80 μM; 24 h) induces the loss of mitochondrial membrane potential in SaOS-2 and 143B osteosarcoma cells in a dose-dependent manner^[1].
Liensinine (40-80 μM; 24 h) dose-dependently regulates the expression of apoptosis- and cell cycle-related proteins in SaOS-2 and 143B osteosarcoma cells in vitro, and inhibits the activation of the JAK2/STAT3 pathway, but exerts no effect on the aforementioned proteins in hFOB 1.19 normal osteoblasts^[1].
Liensinine (20 μM; 24 h) enhances cell viability, reduces apoptosis and cytotoxicity, and inhibits autophagy in an in vitro oxygen-glucose deprivation/reoxygenation ischemia-reperfusion model^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Liensinine (20 mg/kg; i.p.; once daily; for 21 consecutive days) significantly inhibits the growth of subcutaneous hepatocellular carcinoma (HCC) xenografts in male BALB/c nude mice, reduces tumor vascular density, and reshapes the tumor immune microenvironment into an anti-tumor phenotype^[5].
Liensinine (20 mg/kg; i.p.; once daily for 16 consecutive days) significantly inhibits orthotopic HCC tumor progression in male C57BL/6 mice, induces tumor metabolic reprogramming, reduces tumor vascular density, regulates macrophage polarization, and downregulates PD-L1 expression^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

KM mice^[2]
Dosage:

100 mg/kg, 200 mg/kg
Administration:

oral gavage, daily, 10 weeks
Result:

Reduced the gingival index and increased the SOD levels, the CAT, GSH-Px levels and decreased the NO, MDA, and ET levels compared to the control group.

Animal Model:

Institute of Cancer Research (ICR) mice (male, 20-22 g)^[3]
Dosage:
Administration:

5 mg/kg by oral administration; 1 mg/kg by intravenous administration

Result:

The pharmacokinetic parameters of Liensinine in mice

Parameters	po (5 mg/kg)	iv (1 mg/kg)
AUC_(0-t) (ng/mL*h)	18.8 ± 2.7	211.2 ± 54.9
AUC_(0-∞) (ng/mL*h)	19.1 ± 2.8	227.9 ± 60.1
MRT_(0-t)( h)	3.2 ± 0.4	2.6 ± 0.5
MRT_(0-∞) (h)	3.4 ± 0.5	3.5 ± 0.9
t_1/2z (h)	1.9 ± 0.2	3.8 ± 0.8
CL_z/F (L/h/kg)	266.0 ± 41.3	4.7 ± 1.2
V_z/F (L/kg)	708.5 ± 79.9	25.9 ± 11.0
C_max (ng/mL)	5.3 ± 0.2	169.5 ± 53.5

Chemical Information

CAS No. 2586-96-1
Appearance Solid
Masse moléculaire 610.74
Formule C₃₇H₄₂N₂O₆
Color White to off-white
SMILES

OC1=CC=C(C[C@H]2N(C)CCC3=C2C=C(OC)C(OC)=C3)C=C1OC4=CC5=C(C=C4OC)CCN(C)[C@@H]5CC6=CC=C(O)C=C6
Structure Classification
- Alkaloids
- Alkaloid Dimers
- Phenols
- Polyphenols
Initial Source
- Plants
- other families
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (21)

All Cell Proliferation/Viability AssayWBFlow CytometryCell Imaging/StainingRT-PCR

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

Disruption of heme homeostasis by nuclear receptor Nur77 induces pyroptosis through granzyme B-dependent GSDMC cleavage. [Abstract]

2025 Dec 17;10(1):413. PMID: 41407678
Redox Biol

Arylsulfatase K attenuates airway epithelial cell senescence in COPD by regulating parkin-mediated mitophagy. [Abstract]

2025 Jul 31:86:103793. PMID: 40763656

Liensinine purchased from MedChemExpress. Usage Cited in: Redox Biol. 2025 Jul 31:86:103793. [Abstract]

The viability of HBE cells treated with different concentration of Liensinine (LIE) (10, 20, 40, 60, 80 μM) measured by CCK8 assay.

Liensinine purchased from MedChemExpress. Usage Cited in: Redox Biol. 2025 Jul 31:86:103793. [Abstract]

Liensinine (LIE) (40 μM) treatment effectively suppressed autophagy by Western blot.

Liensinine purchased from MedChemExpress. Usage Cited in: Redox Biol. 2025 Jul 31:86:103793. [Abstract]

Liensinine (LIE) (40 μM) improved mitochondrial damage induced by ARSK knockdown, as evidenced by the reductions in intracellular and mitochondrial ROS levels.

Liensinine purchased from MedChemExpress. Usage Cited in: Redox Biol. 2025 Jul 31:86:103793. [Abstract]

SA-β-gal staining results demonstrated that Liensinine (LIE) (40 μM) treatment obviously decreased the percentage of positive cells.

Liensinine purchased from MedChemExpress. Usage Cited in: Redox Biol. 2025 Jul 31:86:103793. [Abstract]

The expressions of IL-6, IL-8 and IL-1β were both relived in HBE cells by Liensinine (LIE) (40 μM).
Int J Biol Sci

Tubule-mitophagic secretion of SerpinG1 reprograms macrophages to instruct anti-septic acute kidney injury efficacy of high-dose ascorbate mediated by NRF2 transactivation. [Abstract]

2022 Aug 8;18(13):5168-5184. PMID: 35982894
Cell Death Dis

Crotonylated BEX2 interacts with NDP52 and enhances mitophagy to modulate chemotherapeutic agent-induced apoptosis in non-small-cell lung cancer cells. [Abstract]

2023 Sep 30;14(9):645. PMID: 37777549
Anim Nutr

Caffeic acid phenethyl ester ameliorates high-fat diet-induced muscle textural deterioration in grass carp (Ctenopharyngodon idellus) by modulating adipose-muscle crosstalk via myostatin-taz signaling. [Abstract]

2026 Feb 6:25:160-174. PMID: 41938616
Chin Med

Targeting G-protein-coupled receptors and gut microbiota: Ge-Lian Qi-Shen decoction elevates GLP-1 to combat non-alcoholic fatty liver disease. [Abstract]

2026 Jan 24;21(1):51. PMID: 41580820
J Ethnopharmacol

Integrating UHPLC-Q-TOF-MS/MS, network pharmacology, bioinformatics and experimental validation to uncover the anti-cancer mechanisms of TiaoPi AnChang decoction in colorectal cancer. [Abstract]

2024 Jul 11:118576. PMID: 39002822
Life Sci

Auto- and paracrine rewiring of NIX-mediated mitophagy by insulin-like growth factor-binding protein 7 in septic AKI escalates inflammation-coupling tubular damage. [Abstract]

2023 Jun 1:322:121653. PMID: 37011875
Genes Nutr

Liensinine alleviates type 2 diabetes mellitus through modulating the pancreatic β cell function and gut microbiota. [Abstract]

2025 Dec 24;20(1):29. PMID: 41444518
Int J Mol Sci

Liensinine Prevents Acute Myocardial Ischemic Injury via Inhibiting the Inflammation Response Mediated by the Wnt/β-Catenin Signaling Pathway. [Abstract]

2025 May 10;26(10):4566. PMID: 40429711
Molecules

Molecular Mechanisms Underlying the Anti-Tumor Activity of Lotus-Derived Alkaloids in Breast Cancer. [Abstract]

2026 Mar 12;31(6):947. PMID: 41900047
J Mol Med (Berl)

Liensinine can improve vascular remodeling in hypertension through the ferroptosis-related TLR4 inflammatory pathway. [Abstract]

2025 Dec 26;104(1):13. PMID: 41452356
J Biol Chem

Activation of Nemo-like Kinase in Diamond Blackfan Anemia suppresses early erythropoiesis by preventing mitochondrial biogenesis. [Abstract]

2024 Jul 9:107542. PMID: 38992436
Adipocyte

The combination of nuclear receptor NR1D1 and ULK1 promotes mitophagy in adipocytes to ameliorate obesity. [Abstract]

2022 Dec;11(1):202-212. PMID: 35410572
Tissue Cell

Liensinine induces autophagy and apoptosis in hepatocellular carcinoma via reactive oxygen species-mediated inhibition of the PI3K/AKT/mTOR pathway. [Abstract]

2026 Jun 12:103:103696. PMID: 42314534
Lett Drug Des Discov

2025 Dec 2.
J Int Med Res

RNA sequencing-based evaluation of the mechanisms underlying the liensinine-mediated inhibition of hypopharyngeal cancer proliferation. [Abstract]

2026 Feb;54(2):3000605261419604. PMID: 41698653
SSRN

2023 Apr 18.
Research Square Print

2023 Mar 24.
J Oncol

Liensinine Inhibits Cell Growth and Blocks Autophagic Flux in Nonsmall-Cell Lung Cancer. [Abstract]

2022 Jul 1:2022:1533779. PMID: 35813859
Oxid Med Cell Longev

Liensinine Inhibits Osteosarcoma Growth by ROS-Mediated Suppression of the JAK2/STAT3 Signaling Pathway. [Abstract]

2022 Jan 25:2022:8245614. PMID: 35116094

Solvant et solubilité

In Vitro:

DMSO : 50 mg/mL (81.87 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.6374 mL

8.1868 mL

16.3736 mL

5 mM

0.3275 mL

1.6374 mL

3.2747 mL

10 mM

0.1637 mL

0.8187 mL

1.6374 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (3.41 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (3.41 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (3.41 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline

Solubility: 20 mg/mL (32.75 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (282 KB)
SDS (480 KB)
- English - EN (480 KB)
- Français - FR (480 KB)
- Deutsch - DE (480 KB)
- Norwegian - NO (480 KB)
- Español - ES (480 KB)
- Swedish - SV (480 KB)
- Italian - IT (480 KB)
- Korean - KR (480 KB)
- Portuguese - PT (480 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Jia F, et al. Liensinine Inhibits Osteosarcoma Growth by ROS-Mediated Suppression of the JAK2/STAT3 Signaling Pathway. Oxid Med Cell Longev. 2022;2022:8245614. Published 2022 Jan 25. [Content Brief]

[2]. Zhang W, et al. Liensinine pretreatment reduces inflammation, oxidative stress, apoptosis, and autophagy to alleviate sepsis acute kidney injury. Int Immunopharmacol. 2023;122:110563. [Content Brief]

[3]. Qiao W, et al. Liensinine ameliorates ischemia-reperfusion-induced brain injury by inhibiting autophagy via PI3K/AKT signaling. Funct Integr Genomics. 2023;23(2):140. Published 2023 Apr 28. [Content Brief]

[4]. Wu MC, et al. Liensinine and neferine exert neuroprotective effects via the autophagy pathway in transgenic Caenorhabditis elegans. BMC Complement Med Ther. 2023;23(1):386. Published 2023 Oct 27. [Content Brief]

[5]. Liu J, et al. Liensinine reshapes the immune microenvironment and enhances immunotherapy by reprogramming metabolism through the AMPK-HIF-1α axis in hepatocellular carcinoma. J Exp Clin Cancer Res. 2025;44(1):208. Published 2025 Jul 15. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.6374 mL	8.1868 mL	16.3736 mL	40.9339 mL
	5 mM	0.3275 mL	1.6374 mL	3.2747 mL	8.1868 mL
	10 mM	0.1637 mL	0.8187 mL	1.6374 mL	4.0934 mL
	15 mM	0.1092 mL	0.5458 mL	1.0916 mL	2.7289 mL
	20 mM	0.0819 mL	0.4093 mL	0.8187 mL	2.0467 mL
	25 mM	0.0655 mL	0.3275 mL	0.6549 mL	1.6374 mL
	30 mM	0.0546 mL	0.2729 mL	0.5458 mL	1.3645 mL
	40 mM	0.0409 mL	0.2047 mL	0.4093 mL	1.0233 mL
	50 mM	0.0327 mL	0.1637 mL	0.3275 mL	0.8187 mL
	60 mM	0.0273 mL	0.1364 mL	0.2729 mL	0.6822 mL
	80 mM	0.0205 mL	0.1023 mL	0.2047 mL	0.5117 mL

Liensinine

21 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Liensinine

Apoptosis Compound Library

Epigenetics Compound Library

Immunology/Inflammation Compound Library

JAK/STAT Compound Library

Kinase Inhibitor Library

MAPK Compound Library

Metabolism/Protease Compound Library

Neuronal Signaling Compound Library

NF-κB Signaling Compound Library

PI3K/Akt/mTOR Compound Library

Protein Tyrosine Kinase Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Anti-Cardiovascular Disease Compound Library

Medicine Food Homology Compound Library

Phenols Library

Glycolysis Compound Library

Pyroptosis Compound Library

Cytoskeleton Compound Library

Glutamine Metabolism Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Alzheimer's Disease Compound Library

Neuroprotective Compound Library

Alkaloids Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Glucose Metabolism Compound Library

Food-Sourced Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Metabolic Enzyme Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Autoimmune Disease Compound Library

Cytokine Inhibitors Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Anti-Brain Cancer Compound Library

Miao Ethnicity Medicine Compound Library

Tibetan Medicine Compound Library

PBCRBS Traditional Chinese Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library